TerminatedPhase 2NCT06045793
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
Studying Cocaine intoxication
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Principal Investigator
- Gregory Sullivan, MDTonix Pharmaceuticals
- Intervention
- TNX-1300 (Injection)(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2024 – 2025
Study locations (6)
- University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
- University Of Maryland Medical Center, Baltimore, Maryland, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Wayne State University, Detroit, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Baylor College of Medicine, Ben Taub Hospital, Houston, Texas, United States
Collaborators
National Institute on Drug Abuse (NIDA) · Premier
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06045793 on ClinicalTrials.gov